Abstract
Purpose :
Several researchers have suggested that the MMP-2 rs243865 (16q13-q21) polymorphism could be associated with an increased risk of developing Age-related Macular Degeneration (AMD). However, previous results remain inconclusive. To clarify this controversy, for the first time a meta-analysis of the relationship between rs243865 of MMP-2 and AMD was performed.
Methods :
We searched five electronic databases (PubMed, Medline, Web of Science, Scopus and Embase) to identify eligible studies. We included 6 independent case-control studies involving 1682 AMD patients and 2295 healthy subjects. The main meta-analysis compared the presence of variant T allele of rs243865 MMP-2 polymorphism among AMD patients as cases versus healthy subjects as controls. Further meta-analyses were performed if three or more studies were available, comparing: a) the presence of CT+TT genotype of rs243865 MMP-2 polymorphism among AMD patients and healthy subjects; b) the presence of CT+TT genotype of rs243865 MMP-2 polymorphism among AMD patients and healthy subjects by age; and c) the presence of CT+TT genotype of rs243865 MMP-2 polymorphism among AMD patients > 65 years old and AMD patients < 65 years old.
The odds ratio (OR) and its 95% confidence interval (CI) were estimated for each study. The results were showed as OR with 95%CI with p-values, and were calculated using a random-effects model. A p-value < 0,05 was considered statistically significant. Cochran`s Q-statistic was used to evaluate heterogeneity. The I2 statistic was used for estimation of inconsistency in meta-analysis. Begger`s funnel plot was drawn to assess publication bias. Sensitivity analysis was performed excluding individual studies. The meta-analysis was performed using the computer software package RevMan 5.0. Deviation of genotype frequencies from the Hardy-Weinberg equilibrium (HWE) in healthy subjects was assessed by X2 test.
Results :
Our results showed that there was no significant association between variant T allele (p-value = 0,10, OR (95%CI) = 0,95 (0,82-1,10)) or CT+TT genotypes (p-value= 0,16, OR (95%CI) = 0,92 (0,76-1,12)) of rs243865 MMP-2 polymorphism and the presence of AMD.
Conclusions :
The rs243865 MMP-2 polymorphism was not associated with an increased risk of developing AMD. MMP-2 (-1306 C>T) promoter variant is unlikely to have a major role in AMD risk susceptibility.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.